Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191373 · ClinicalTrials.gov registry record · Phase 2
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00191373 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 66 participants.
The verdict
NCT00191373, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion administered on subsequent cycles.
Interventions
- DRUG Trastuzumab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2002-03 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191373
The ClinicalTrials.gov registry entry for NCT00191373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT00191373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00191373 about?
NCT00191373 is a clinical study titled "A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease". This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion administered on subsequent cycles.
What is the current status of trial NCT00191373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2002-03. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00191373?
The interventions under investigation include: Trastuzumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00191373?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.